Comments

Sarepta Therapeutics

Q: What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

SRPTNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$120.25

0.000.00%

Pre-Market: 4:16 PM EDT

Sarepta Therapeutics (SRPT) Forecast

News Earnings Sarepta Therapeutics (SRPT) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Overview Rating

Speculative

Technicals Analysis

0100

Financials Analysis

0100

Sarepta Therapeutics (NASDAQ:SRPT) Stock Quotes, Forecast and News Summary

Sarepta Therapeutics Stock (NASDAQ: SRPT) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	142.00 / 955.08K
Day Range	- - -
52 Wk Range	89.92 - 173.25
Market Cap	$11.49B
P/E Ratio	78.08
Dividend Yield	-
Exchange	NASDAQ
RSI	45
Short Interest	6.36%
Days to Cover	3.87

Recent News

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.

Vandana Singh

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.

Lekha Gupta

Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?

Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.

Lekha Gupta

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug

Sep

Oct

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	142.00 / 955.08K
Day Range	- - -
52 Wk Range	89.92 - 173.25
Market Cap	$11.49B
P/E Ratio	78.08
Dividend Yield	-
Exchange	NASDAQ
RSI	45
Short Interest	6.36%
Days to Cover	3.87

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Sarepta Therapeutics (SRPT) stock?

You can purchase shares of Sarepta Therapeutics (NASDAQ:SRPT) through any online brokerage.

View our list of the best stock brokerages

Who are Sarepta Therapeutics (SRPT) competitors?

Other companies in Sarepta Therapeutics’s space includes: Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Roivant Sciences (NASDAQ:ROIV), Amgen (NASDAQ:AMGN) and United Therapeutics (NASDAQ:UTHR).

What is the forecast, or price target, for Sarepta Therapeutics (SRPT) stock?

Sarepta Therapeutics has a consensus price target of $175.72.

What is the current price for Sarepta Therapeutics (SRPT)?

The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $120.25 last updated December 18, 2024 at 4:16 PM EST.

Does Sarepta Therapeutics (SRPT) pay a dividend?

There are no upcoming dividends for Sarepta Therapeutics.

When is Sarepta Therapeutics (NASDAQ:SRPT) reporting earnings?

Sarepta Therapeutics’s Q4 earnings are confirmed for Wednesday, February 26, 2025.

Is Sarepta Therapeutics (SRPT) going to split?

There is no upcoming split for Sarepta Therapeutics.

What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.